ProQR Therapeutics (PRQR) Revenue (2012 - 2026)

ProQR Therapeutics (PRQR) has reported Revenue for 15 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.

• Quarterly Revenue fell 55.01% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (down 29.27% YoY) and the FY2025 annual result came in at $18.1 million, down 15.86% from the prior year.
• Revenue declined to $2.3 million in Q1 2026 per PRQR's latest filing, from $5.3 million in the prior quarter.
• Over the last five years, Revenue for PRQR reached as high as $7.2 million in Q2 2024 and fell as low as $745360.0 in Q1 2023.
• A 5-year average of $3.1 million and a median of $3.3 million in 2025 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue sank 90.66% — and 2024, when it soared 579.39%.
• Year by year, Revenue stood at $819327.1 in 2022, then jumped by 356.11% to $3.7 million in 2023, then soared by 31.15% to $4.9 million in 2024, then climbed by 8.85% to $5.3 million in 2025, then sank by 56.63% to $2.3 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $2.3 million, $5.3 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.